Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Colon cancer (adenocarcinoma of the colon), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
3-year recurrence HR 0.
3-year DFS 86.
DFS HR 0.
Chemotherapy use 15% vs 28% with non-inferior RFS.
pCR 68%, major pathologic response 95%; 3-year DFS 100%.